Brief: Aurinia Pharmaceuticals Q4 EPS USD -0.19
15/02/2024 11:00
Feb 15 (Reuters) - Aurinia Pharmaceuticals Q4 net income USD -26.875 million. * Q4 operating income USD -29.674 million * Q4 product revenue USD 42.315 million * Q4 pretax profit USD -26.416 million
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death